Brolucizumab
- Generic Name
- Brolucizumab
- Brand Names
- Beovu
- Drug Type
- Biotech
- CAS Number
- 1531589-13-5
- Unique Ingredient Identifier
- XSZ53G39H5
Overview
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
Background
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
Indication
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath